NCT04130997Phase 3Active not recruiting

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Study sponsor: TG Therapeutics, Inc. · TGTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2032-05-31Estimated
Enrollment · participants1100Estimated
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 1 Feb 2030. After: 31 May 2032.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview